v3.26.1
Revenue
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Product revenue, net
On November 8, 2024, the Company was notified by the FDA that the Company’s BLA was approved, allowing for the marketing of AUCATZYL in the United States for the treatment of adult patients with r/r B-ALL. The first sale of AUCATZYL in the United States occurred in January 2025. In November 2025, the National Institute for Health and Care Excellence (“NICE”) recommended AUCATZYL for use in the NHS in England and Wales as a treatment option for adult patients (age 26 and older) with r/r B-ALL. The first sale of AUCATZYL in the United Kingdom occurred in January 2026.
Product revenue, net recognized after estimated deductions for rebates and chargebacks for the three and six months ended June 30, 2026, and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Product revenue, net
$45,672 $20,923 $71,890 $29,905 
Accounts receivable from contracts with customers
Accounts receivable, net as of June 30, 2026 and December 31, 2025 was $44.4 million and $24.0 million, respectively. An allowance for lifetime expected credit losses on accounts receivable is measured using historical credit loss experience, conditions at the end of each reporting period, and reasonable and supportable forecasts that affect collectability. Expected credit losses as of June 30, 2026 and December 31, 2025, based on the Company's third-party agreements are immaterial.
Accruals for rebates and chargebacks
Current accruals for rebates and chargebacks as of June 30, 2026 were as follows (in thousands):
Rebates
Chargebacks
Total
As of December 31, 2025
$3,658 $1,333 $4,991 
Rebate and chargeback accruals related to product revenue recognized in the period
6,711 2,948 9,659 
Payments and credits made
(1,995)(2,615)(4,610)
Adjustments related to prior period sales
— (847)(847)
As of June 30, 2026
$8,374 $819 $9,193